SCHEMBL14727906

SCHEMBL14727906

COP(=O)(O)OCCCOP(=O)(O)OCCCCCCN

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPAR3 Q9UBY5 6/20 0.41
LPAR2 Q9HBW0 5/20 0.41
LPAR1 Q92633 4/20 0.41
ITPR3 Q14573 1/20 0.41
ITPR1 Q14643 1/20 0.41
PLA2G2C Q5R387 1/20 0.39
P2RY10 O00398 5/20 0.37
GABBR2 O75899 1/20 0.36
CYP1A2 P05177 1/20 0.36
TSHR P16473 1/20 0.36
THPO P40225 1/20 0.36
GABBR1 Q9UBS5 1/20 0.36
FDPS P14324 1/20 0.36
GPR34 Q9UPC5 2/20 0.36
LMNA P02545 2/20 0.35
BLM P54132 2/20 0.35
PLA2G2A P14555 1/20 0.35
CYP3A4 P08684 1/20 0.34
NFKB1 P19838 1/20 0.34
PMP22 Q01453 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19237471 0.96 LPAR3 (0.44) LPAR3LPAR2LPAR1ITPR3ITPR1
SCHEMBL2755680 0.96 LPAR3 (0.44) LPAR3LPAR2LPAR1ITPR3ITPR1
SCHEMBL26079101 0.96 LPAR3 (0.44) LPAR3LPAR2LPAR1ITPR3ITPR1
SCHEMBL17052326 0.88 ITPR3 (0.49) LPAR3LPAR2LPAR1ITPR3ITPR1
SCHEMBL23631720 0.88 ITPR3 (0.47) LPAR3LPAR2LPAR1ITPR3ITPR1
SCHEMBL23631717 0.86 ITPR3 (0.49) LPAR3LPAR2LPAR1ITPR3ITPR1
SCHEMBL20169135 0.85 LPAR3 (0.55) LPAR3LPAR2LPAR1PLA2G2CP2RY10
SCHEMBL14727907 0.85 LPAR3 (0.53) LPAR3LPAR2LPAR1ITPR3ITPR1
SCHEMBL19699811 0.84 LPAR3 (0.43) LPAR3LPAR2LPAR1ITPR3ITPR1
SCHEMBL9496121 0.83 LPAR3 (0.62) LPAR3LPAR2LPAR1PLA2G2CTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9045750-B2 Humanized lewis-Y specific antibody-based delivery of dicer substrate siRNA (D-siRNA) against STAT3 MA YUELONG (US) 2015-06-02 US disclosed
US-20130052731-A1 HUMANIZED LEWIS-Y SPECIFIC ANTIBODY-BASED DELIVERY OF DICER SUBSTRATE siRNA (D-siRNA) AGAINST STAT3 MA YUELOG (US) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130052731-A1 HUMANIZED LEWIS-Y SPECIFIC ANTIBODY-BASED DELIVERY OF DICER SUBSTRATE siRNA (D-siRNA) AGAINST STAT3 AGO2, HNRNPH3, HCLS1 LPAR3 1809/4885LPAR2 3291/4885LPAR1 2922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.